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Sepsis-associated acute kidney injury (AKI) is a significant problem in criti-
cally ill children and adults resulting in increased morbidity and mortality.
Fundamental mechanisms contributing to sepsis-associated AKI are poorly
understood. Previous research has demonstrated that peroxisome proliferator-
activated receptor a (PPARa) expression is associated with reduced organ sys-
tem failure in sepsis. Using an experimental model of polymicrobial sepsis, we
demonstrate that mice deficient in PPARa have worse kidney function, which
is likely related to reduced fatty acid oxidation and increased inflammation.
Ultrastructural evaluation with electron microscopy reveals that the proximal
convoluted tubule is specifically injured in septic PPARa deficient mice. In
this experimental group, serum metabolomic analysis reveals unanticipated
metabolic derangements in tryptophan-kynurenine-NAD+ and pantothenate
pathways. We also show that a subgroup of children with sepsis whose gen-
ome-wide expression profiles are characterized by repression of the PPARa
signaling pathway has increased incidence of severe AKI. These findings point
toward interesting associations between sepsis-associated AKI and PPARa-dri-
ven fatty acid metabolism that merit further investigation.
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Introduction
Sepsis is an all-too-common, life-threatening condition
that afflicts both old and young (Mayr et al. 2014;
Weiss et al. 2015). Sepsis has traditionally been viewed
as a syndrome of organ system failure caused by
immune dysregulation in the setting of significant infec-
tion (Angus and van der Poll 2013; Hotchkiss et al.
2013). Recent findings, however, have pointed to dis-
ruption of cellular metabolism as a contributing cause
of organ failure in sepsis (Lee and H€uttemann 2014;
Singer 2014). The kidney is particularly sensitive to sep-
tic insult and acute kidney injury (AKI) is a common
complication of sepsis that increases both patient mor-
bidity and mortality (Alobaidi et al. 2015; Fitzgerald
et al. 2016).
Our previous research evaluating children with septic
shock using genome-wide expression profiling of circulat-
ing leukocytes identified a subpopulation with more sev-
ere disease, worse organ system dysfunction, and
increased mortality. This cohort of children demonstrated
profound suppression of the peroxisome proliferator-acti-
vated receptor alpha (PPARa) signaling pathway (Wong
et al. 2009b). PPARa is a ligand-activated nuclear hor-
mone receptor transcription factor that regulates the
expression of genes related to inflammation and cellular
lipid metabolism (Wahli and Michalik 2012; Bougarne
et al. 2018). Using an experimental model of polymicro-
bial sepsis, we previously showed that mice lacking
PPARa expression (Ppara/ mice) have decreased sur-
vival, consistent with our clinical transcriptomic data
(Standage et al. 2012). Furthermore, we recently demon-
strated that Ppara/ mice show evidence of greater car-
diac and kidney injury in sepsis than do wild-type (WT)
mice (Standage et al. 2016).
In the current work, we sought to further evaluate the
role of PPARa in sepsis-associated AKI. Using multiple
modalities, we show that Ppara/ mice have inflamma-
tory and metabolic derangement associated with func-
tional renal failure and markers of kidney injury. The
proximal convoluted tubule of the nephron is specifically
damaged in Ppara/ mice. Additionally, we report clini-
cal findings that children with septic shock whose gen-
ome-wide expression profiles are characterized by PPARa
signaling pathway suppression have greater incidence of
severe AKI.
Materials and Methods
All raw data, images, statistical analysis scripts, and
supplementary methods and figures are deposited on
the Open Science Framework (https://doi.org/10.17605/
osf.io/2jfwx).
Animal studies
All experiments were approved by the University of
Washington Institutional Animal Care and Use Commit-
tee. We used 12- to 14-week old male C57Bl/6J mice and
age-matched Ppara/ mice (B6.129S4-Pparatm1Gonz/J)
raised in our own colonies from breeding pairs purchased
from The Jackson Laboratory (Bar Harbor, Maine; Stock
Nos: 000664 and 008154, respectively). Sepsis was induced
using the cecal ligation and puncture (CLP) model as
previously described (Buras et al. 2005; Nemzek et al.
2008; Standage et al. 2012, 2016). Sham-operated animals
underwent the same procedure, including exteriorization
and manipulation of their cecum, but the cecum was not
ligated or punctured. All mice received postoperative sal-
ine, buprenorphine, and imipenem. Because septic mice
do not eat postoperatively, chow was removed from all
cages, including those of the sham groups to control for
the fasted state. For the metabolomics and electron
microscopy experiments, cohorts of unoperated, fed, con-
trol mice were used to represent healthy baseline. Mice
were euthanized and tissue samples were collected 24 h
after the operation.
Blood and urine biomarker assays
Blood was collected by direct cardiac puncture and serum
frozen was prepared at 80°C until batch analysis. Serum
was subsequently analyzed for blood urea nitrogen (BUN)
(Pointe Scientific, Canton, Michigan) and creatinine (Dia-
zyme Laboratories, Poway, California) using enzyme-based
colorimetric assays. Both assays provided values signifi-
cantly higher than expected norms for mice in all study
cohorts. Consistent with multiple prior experiments, the
sham mice appeared very well and scored low on our
clinical illness severity scoring system (not shown), while
the CLP mice were visibly ill. The elevated values were con-
sidered an artifact of the analytical system and they are
reported here unaltered with the analysis focused on rela-
tive differences between groups, assuming a normal base-
line in the WT sham cohort.
Urine was collected at 24 h postoperatively using spe-
cial cages with wire mesh bottoms. Mice were placed sin-
gly in urine collection cages at the 12-h monitoring point
until the 24-h monitoring point. Collected urine was fro-
zen at 80°C until batch analysis. Urine total protein
levels were measured using the Pierce BCA assay (Thermo
Fisher Scientific, Waltham, Massachusetts).
Kidney tissue gene expression analysis
Kidneys were collected 24 h after CLP and snap frozen
in liquid nitrogen. Total RNA was purified from tissue
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samples using Trizol reagent (Thermo Fisher Scientific,
Waltham, Massachusetts). cDNA was created using a
High Capacity cDNA Reverse Transcription Kit and
qRT-PCR was performed using a Sensimix II kit (Bio-
line, Taunton, Massachusetts) and TaqMan gene expres-
sion assays for kidney injury marker 1 (KIM-1,
Havcr1), neutrophil gelatinase-associated lipocalin
(NGAL, Lcn2), interleukin 6 (Il6), IL-1b (Il1b), tumor
necrosis factor a (Tnfa), fatty acid translocase (cluster
of differentiation 36, Cd36), fatty acid transport pro-
teins 1 and 2 (Slc27a1, Slc27a2), medium chain acyl-
CoA dehydrogenase (Acadm), very long-chain acyl-CoA
dehydrogenase (Acadvl), acyl-coenzyme A oxidase 1
(Acox1), acetyl-CoA carboxylase, carnitine palmitoyl-
transferase 1a and 2 (Cpt1a and Cpt2) and peroxisome
proliferator-activated receptor a (PPARa) (Thermo
Fisher Scientific, Waltham, Massachusetts). Relative gene
expression was calculated using the DD-Ct method nor-
malizing the results to WT sham condition. On prelim-
inary review of the gene expression data, it became
apparent that the PPARa primer/probe set had been
contaminated and this target was thus eliminated from
final analysis.
Protein immunoblotting
Total protein was extracted from snap frozen kidney tis-
sue using RIPA buffer and 20 lg loaded onto 4–12% Bis-
Tris gradient gels for protein gel electrophoresis. After
transfer, PVDF membranes were stained with Ponceau
reagent and imaged to assess protein loading. Washed
membranes were subsequently blocked with 5% BSA and
then incubated overnight at 4°C in a solution containing
both primary antibodies. Rabbit polyclonal anti-ACADM
antibody was obtained from Abcam (ab92461, Lot
#: GR15062-13; Cambridge, Massachusetts). Rabbit poly-
clonal anti-ACADVL was obtained from Santa Cruz
Biotechnology (sc-98338, Lot #: A2814; Dallas, Texas).
Membranes were subsequently incubated with HRP-con-
jugated goat polyclonal anti-rabbit antibody (Abcam, Lot
#: unavailable; ab6721), developed using SuperSignal West
Pico Chemiluminescent Substrate (Life Technologies,
Carlsbad, California), and imaged on a Bio-Rad Chemi-
doc imager (Bio-Rad, Hercules, California). While neither
of our primary antibodies have undergone rigorous vali-
dation with knockout controls, their use has been
reported in many other studies with findings consistent
with specific regulation of their target proteins (Mells
et al. 2012; Choi et al. 2014; Tan et al. 2014; Becker et al.
2018; Liu et al. 2018; Stancic et al. 2018; Zheng and Cai
2019).
Relative protein abundance was measured by densito-
metry using ImageJ (National Institutes of Health,
Bethesda, MD). To normalize for protein loading, the
band density of target proteins was divided by the den-
sity of the total protein Ponceau staining in the region
of the membrane at the predicted molecular weight of
the protein of interest.
Electron microscopy
Tissue samples for electron microscopy were obtained at
the same time for control and experimental mice under
the same conditions. Tissue cut from the renal cortex
was fixed with 4% glutaraldehyde in sodium cacodylate
buffer, mounted in Epon Araldite epoxy resin blocks,
cut by ultramicrotome and visualized on a Hitachi H-
7650 transmission electron microscope. Electron micro-
graphs of 6–9 randomly selected proximal tubular seg-
ments were captured for each subject and scored by a
blinded reader for evidence of injury. The scoring system
focused on specific ultrastructural changes and is given
in Table S2.
Serum metabolomics
Fifty-microliters of serum underwent methanol extraction
and subsequent targeted liquid chromatography–mass
spectroscopy. Relative metabolite abundance was quanti-
fied by measuring the detected product ion peak area. A
detailed description of the metabolomic analysis is pro-
vided in the Supplemental Material.
Assessment of acute kidney injury in
critically ill children with septic shock
Acute kidney injury was analyzed retrospectively in a
cohort of pediatric patients admitted to intensive care
units with a diagnosis of septic shock as part of an
ongoing, multicenter genomic and clinical research pro-
gram. The study was approved by institutional review
boards at each participating institution and has been
described previously (Shanley et al. 2007; Cvijanovich
et al. 2008; Wong et al. 2009b; Basu et al. 2011). Briefly,
blood was obtained from each subject within 24 h of
admission to the ICU. RNA was extracted from whole
blood and genome-wide expression profiles generated
using Affymetrix gene chip technology. Clinical and lab-
oratory data were collected according to each institu-
tion’s standard of care and 28-day mortality recorded.
All subjects were previously described in studies report-
ing two endotypes of pediatric septic shock, endotypes
A and B, based on the expression patterns of 100 genes
(Wong et al. 2011, 2015). The 100 endotyping genes
correspond to adaptive immunity, the glucocorticoid
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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receptor signaling pathway, and the PPARa signaling
pathway. The majority of these genes is repressed in
endotype A subjects, relative to endotype B subjects.
Additionally, allocation to endotype A is independently
associated with increased odds of persistent multiple
organ failure and mortality.
One hundred and ninety-three subjects with septic
shock had both endotyping and clinical data sufficient
for AKI staging. Endotype classification was assigned to
each subject based on their gene expression profile, as
previously described. Diagnosis of AKI was based on
the Kidney Disease: Improving Global Outcomes
(KDIGO) criteria. Severe AKI was defined as stage 3
(creatinine level ≥ 3 times baseline) and was assessed
on day 3 of PICU admission. This cutoff was used
because this KDIGO stage has been associated with
increased mortality rate in prior studies (Sutherland
et al. 2015; Kaddourah et al. 2017). The timing of AKI
diagnosis was chosen because: (1) most PICU patients
with AKI will develop AKI by day 3, (2) 3 days allow
enough time for development of severe AKI, and (3)
the passage of time allows for increased creatinine attri-
butable to “prerenal” conditions to improve (Basu et al.
2014).
None of the subjects had baseline, pre-illness crea-
tinine recorded. Baseline creatinine was therefore esti-
mated using two previously validated different
methods. For subjects with recorded height, we esti-
mated baseline creatinine from the calculated body
surface area (Zappitelli et al. 2008). For the remaining
patients, baseline creatine was estimated with a method
accounting for age and gender (Pottel et al. 2008;
Hessey et al. 2017).
Statistical analysis
Statistics were computed using R version 3.5.1 (https://cra
n.r-project.org). Raw data and analysis scripts are made
available on the Open Science Framework (https://doi.
org/10.17605/osf.io/2jfwx). As we evaluated the effect of
two factors, mouse strain and experimental condition, on
outcome indices, we first ran two-factor analyses of vari-
ance (ANOVAs) with an interaction term. If the interac-
tion term was significant, we computed post hoc pairwise
comparisons between contrasts of interest defined a pri-
ori. If no interaction effect was identified, the two-factor
ANOVA model was repeated without an interaction term
to evaluate for main effects. If statistically significant main
effects were identified, pairwise comparisons were subse-
quently made between factor levels. P values were
adjusted for multiple comparisons using a false discovery
rate of 0.05. For the urine protein experiment, the
Welch’s t-test for unequal variances was used for simple
comparisons between two groups. The Fisher exact test
was used to compare the fraction of anuirc mice between
genotypes. An alpha of 0.05 was used for all statistical
tests.
In children with septic shock, we used multivariable
logistic regression to evaluate for an association between
endotype assignment and AKI. The model included terms
to control for severity of illness (PRISM score) and age
(Wong et al. 2009b; Stenson et al. 2018).
Results
Ppara/ mice have worse kidney function in
experimental polymicrobial sepsis
To investigate the effect of PPARa expression on kidney
function in sepsis, WT and Ppara/ mice underwent
CLP to induce polymicrobial sepsis or sham surgery.
Serum biomarkers for kidney injury, BUN and crea-
tinine, were higher in Ppara/ mice, but not WT mice
24 h after CLP, indicating worse renal function in sep-
sis in the Ppara/ cohort (Fig. 1A). Although the
sham operation represents a minor injury and there
appeared to be a slight elevation in BUN and creatinine
levels in the Ppara/ sham group, no statistically sig-
nificant differences were noted between WT and
Ppara/ mice in the sham condition. Likewise, the
minor trends in biomarker elevation in the WT mice
between sham and CLP conditions were not significant
(Table 1).
Measurement of urine protein as a marker of kidney
injury was complicated by a large proportion of anuric
Ppara/ mice. The majority of septic Ppara/ mice had
no urine output between 12 and 24 h after CLP, indicat-
ing very poor kidney function, while only one WT mouse
was anuric (Fig. 1B). No sham mice were anuric. When
assessed in the sham cohorts, urine protein was elevated
in Ppara/ compared to WT mice (Fig. 1C). This bio-
marker was not analyzed in the CLP cohorts due to con-
cern for significant survivor bias.
Tissue mRNA expression of markers of
kidney injury and inflammation are more
elevated in septic Ppara/ mice
To assess direct tissue injury, we measured kidney
mRNA expression of KIM-1 and NGAL, which are ele-
vated in renal failure, and the inflammatory markers
IL-6, IL-1b, and TNFa. Kidney KIM-1, NGAL, and
IL-6 expression was dramatically increased in CLP
operated Ppara/ mice compared with the sham con-
dition. WT CLP mice only showed elevation in NGAL
2019 | Vol. 7 | Iss. 10 | e14078
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expression, which was still lower than the level
observed in Ppara/ mice (Fig. 2). The slight upward
trends in WT KIM-1 and IL-6 expression did not
reach statistical significance. TNFa and IL-1b had no
interaction effect between mouse strain and experimental
















































































Figure 1. Ppara/ mice exhibit renal failure in experimental sepsis. 24 h after CLP or sham surgery blood and urine were collected. (A)
Serum markers of kidney injury, BUN and creatinine were specifically elevated in Ppara/ mice. No statistically significant differences were
noted between WT and Ppara/ mice in the sham condition or in WT mice between sham and CLP conditions. Interaction term for a two-
factor ANOVA had a P value < 0.01 for both biomarkers and post hoc pairwise comparisons also differed significantly. *P < 0.001 for
comparison between strains within condition, #P < 0.001 for comparison between conditions within strain. n = 8 WT/Sham; 8, Ppara//
Sham; 9 WT/CLP; 7, Ppara//CLP. (B) Six of 10 septic Ppara/ mice were anuric when urine was collected between the 12- and 24-h time
points. Only 1 of 10 WT mice was anuric after CLP (Fisher exact test, P = 0.057). (C) Urine was analyzed for protein only in the sham
group due to survivor bias in the CLP cohort. Even with sham surgery, Ppara/ mice exhibited elevated protein levels in their urine (Welch’s
t-test, P < 0.01). n = 7/group.
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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identified in both, indicating increased expression in
the CLP over the sham condition irrespective of geno-
type (Fig. S1).
Expression of enzymes related to transport
and oxidation of fatty acids is lower in
Ppara/ kidneys
Because the renal cortex relies primarily on lipid sub-
strate for energy provision (Weidemann and Krebs
1969), we evaluated expression of genes related fatty
acid metabolism. Gene expression of enzymes associated
with fatty acid oxidation (FAO) (Acadm, Acadvl, and
Acox1) and fatty acid transport (Slc27a1, Slc27a2, Cpt2)
was lower in Ppara/ kidney tissue than in WT kidney
in both sham and CLP conditions (Fig. 3A). Expression
levels did not differ between conditions within each
genotype. Kidney expression of fatty acid translocase
(Cd36) was, however, higher in the CLP mice than in
the sham without difference between genotypes. No dif-
ferences were observed in the expression of Cpt1a, the
primary transporter of fatty acids into the mitochon-
dria, between either strain or condition (Figure S2).
Consistent with their gene expression, protein levels of
ACADM and ACADVL were lower in the Ppara/
kidney (Fig. 3B).
Transmission electron microscopy reveals
more severe ultrastructural damage in
Ppara/ proximal tubules
We previously reported that Ppara/ mice had worse
kidney histological injury scores on evaluation by light
microscopy (Standage et al. 2016). Specifically, we
observed multifocal areas of tubular degeneration and
necrosis in Ppara/ kidneys, characterized by tubular
dilatation with epithelial flattening, cytoplasmic vacuoliza-
tion, and nuclear dropout (Fig. 4A). These findings, cou-
pled with a recognition that the Ppara/ proximal
tubule would likely be specifically vulnerable to injury
because of its high reliance on FAO, motivated an analy-
sis of proximal tubular ultrastructure using electron
microscopy.
The total proximal tubule injury score was higher for
Ppara/ mice after CLP than WT (Fig. 4B). Ppara/
proximal tubular epithelial cells had far greater disrup-
tion of their brush border, more numerous endocytic



































































Figure 2. Tissue markers of injury and inflammation are increased in Ppara/ mice in sepsis. mRNA expression of renal injury markers KIM-1
and NGAL as well as the inflammatory marker IL-6 was more elevated in Ppara/ mice than WT mice 24 h after CLP. No statistically significant
differences were noted in KIM-1 and IL-6 expression between WT and Ppara/ mice in the sham condition or in WT mice between sham and
CLP conditions. *P < 0.01 for comparison between strains within condition, #P < 0.01 for comparison between conditions within strain. n = 5
WT/Sham; 5 Ppara//Sham; 8 WT/CLP; 5, Ppara//CLP.
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(Fig. S3). Regarding lysosome abundance, we observed
main effects for both strain and condition, but no inter-
action between them. Ppara/ mice have lipid droplets
in their proximal tubular epithelial cells in the control
condition that do not change in abundance with sepsis.
Control WT mice, however, demonstrate no lipid dro-
plets, but develop them after CLP in equivalent abun-
dance to the Ppara/ mice. We neither saw differences
in the loss of basal interdigitating processes nor any
changes in mitochondrial structure or integrity (Fig. S3).
Visualized glomeruli and distal convoluted tubule seg-
ments appeared normal.
Serum metabolomic analysis reveals
evidence of renal failure and metabolic
derangement in Ppara/ mice
The kidney plays a central role in regulating the
metabolic milieu in both health and stress states. We
therefore undertook a serum metabolomic analysis of
Ppara/ and WT mice in control, sham, and CLP
conditions 24 h after surgery. Sham mice were fasted
to replicate the self-imposed anorexic state exhibited
by septic mice. Rather than evaluate every possible
comparison individually, we focused our analysis on
five important contrasts that would illuminate
metabolic differences between the control, sham, and
CLP conditions in WT mice and show how Ppara/
mice differed from WT in each condition (Fig. 5).
Pathway analysis for each comparison was subse-
quently performed using MetaboAnalyst (http://www.
metaboanalyst.ca/) (Xia and Wishart 2016; Chong
et al. 2018).
Comparison 1
Metabolites that differed between Ppara/ and WT mice in
the control condition and across all conditions (main effect
for strain) related to three important biological processes
associated with renal function and energy metabolism. First,
serum levels of metabolites associated with the urea cycle












































































































































































































Figure 3. Tissue expression of enzymes related to fatty acid transport and oxidation are lower in Ppara/ mice. (A) mRNA expression
of genes associated with lipid metabolism was lower in Ppara/ mice than WT irrespective of condition. No interaction effect was
noted on two-factor ANOVA, but main effect for strain was significant (†P < 0.05). n = 5 WT/Sham; 5 Ppara//Sham; 8 WT/CLP; 5
Ppara//CLP. (B) Protein levels of ACADM and ACADVL, two enzymes involved with FAO, were lower in Ppara/ mice. Again, only
main effects for strain were observed in the ANOVA model (†P < 0.05). * indicates nonspecific bands. A representative western blot is
displayed. All immunoblot images are available in online data repository. n = 8 WT/Sham; 7 Ppara//Sham; 9 WT/CLP; 6 Ppara//
CLP.
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Ppara/ versus WT mice (Fig. 6A). Additionally, benzoic
acid, which is involved with excretion of nitrogenous waste,
was lower in Ppara/ mice. This indicates a higher degree
of protein turn over in Ppara/ mice, which is consistent
with previous findings demonstrating that PPARa activation
suppresses amino acid metabolism and attendant urea cycle
function (Tremblay and Qureshi 1993; Feoli-Fonseca et al.
1996; Kersten et al. 2001; Makowski et al. 2009; Brosnan
and Brosnan 2010; Kersten 2014).
Second, carnitine is lower in the serum of Ppara/
mice. Carnitine is necessary for fatty acid transport and
oxidation (Fig. 6B). Its production, which is primarily
localized to the kidney (Rebouche and Engel 1980; Guder
and Wagner 1990), is enhanced by PPARa transcriptional
regulation (Makowski et al. 2009; Ringseis et al. 2012).
Other quaternary ammonium compounds, structurally
similar to carnitine (trimethylamine and trimethylamine-
N-oxide) were also lower in Ppara/ mice.
Third, multiple metabolites associated with the trypto-
phan-kynurenine-NAD+ pathway (tryptophan, L-kynure-
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Figure 4. Septic Ppara/ mice exhibit more damage to the proximal tubule. (A) Representative H and E stained sections of renal cortex at
209 magnification. Ppara/ tubules show dilatation (D), epithelial flattening (black arrow heads), vacuolization (white arrow heads), and
nuclear drop out (N). Scale bar = 50 lm. (B) Formal scoring on ultrastructural evaluation of proximal tubular segments demonstrates worse
injury in Ppara/ mice. Interaction term in two-factor ANOVA significant (P = 0.00011) with subsequent post hoc pairwise contrasts (*P < 0.05
for comparison between strains within condition, #P < 0.05 for comparison between conditions within strain). (C) Representative electron
micrographs in longitudinal and transverse cross-section show brush border (BB) disruption, increased autophagosome, and autolysosome
abundance (black arrow heads), and greater lipid droplet number and size (white arrow heads) in the Ppara/ mice. Nucleus (N).
800 9 magnification. Scale bar = 8 lm. All scored electron micrographs are available in online data repository. n = 4 WT/Control; 3 Ppara//








Figure 5. Serum metabolomics analysis comparisons. Serum
metabolite levels were analyzed in all three conditions for both
genotypes to evaluate for important metabolic differences. Five
direct comparisons were made to highlight contrasts of greatest
interest. n = 10 WT/Control; 10 Ppara//Control; 10 WT/Sham; 5
Ppara//Sham; 6 WT/CLP; 8 Ppara//CLP.
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between WT and Ppara/ mice (Fig. 6C). This pathway
subserves many biological functions, but importantly,
NAD+ production is its primary output (Cervenka et al.
2017). NAD+ is an essential energy carrier for many
bioenergetic reactions. MetaboAnalyst pathway analysis
identified tryptophan metabolism as the most dysregu-
lated pathway in this comparison (Fig. S4).
Comparison 2
Metabolic signatures characteristic of fasting distinguished
control and sham conditions in WT mice. Serum ketones
(acetoacetate, 3-hydroxybutyric acid, and 2-hydroxyisova-
leric acid) were dramatically upregulated (Fig. 7A). Levels































































































































































































Figure 6. Metabolites that differ between WT and Ppara/ mice in the control condition and across all conditions (Comparison 1). (A)
Metabolites associated with the urea cycle and nitrogen excretion differ at baseline between WT and Ppara/ mice. (B) Carnitine and
associated quaternary ammonium compounds are lower in Ppara/ mice. (C) Ppara/ mice show derangement in metabolites associated with
the tryptophan-kynurenine-NAD+ pathway. See Figure S4A for calculated fold change and P values. *P < 0.05 for comparison between strains
within condition, #P < 0.05 for comparison between previous condition within strain, †P < 0.05 for main effect only for strain across all
conditions, and §P < 0.05 for main effect only for comparison with previous condition.
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breakdown (Long et al. 1981; Stortz et al. 2018), were
increased in the sham animals indicating the mobilization
of amino acids from muscle (Fig. 7B). Levels of several
gluconeogenic (alanine, arginine, proline, methionine,
tryptophan, and tyrosine) and ketogenic (lysine, trypto-
phan, and tyrosine) amino acids were reduced, likely due
to consumption in the fasted state. Metabolites associated
with carbohydrate metabolism (glucose, glyceraldehyde,
erythrose, lactate, and pyruvate) were decreased (Fig. 7C).
MetaboAnalyst identified pathways related to carbohy-
drate, amino acid, and ketone body metabolism as the
most different between control and sham states in WT
mice (Fig. S5).
Comparison 3
The primary difference between Ppara/ and WT mice
in the sham condition is that ketone abundance was
lower in Ppara/ mice (Fig. 7A, Fig. S6). We observed
this previously (Standage et al. 2017) and attribute the
difference to decreased FAO, which is needed to generate
ketones (Kersten et al. 1999; Leone et al. 1999).
Comparison 4
Two important features characterize the metabolic dif-
ferences between the sham and CLP conditions in WT
mice. First, metabolites associated with stress responses
dramatically increased (Fig. 8A). Serum glucuronate
levels rose nearly 160-fold in the CLP condition and
inositol, its immediate biosynthetic precursor, was also
increased. Glucuronidation is a host defense mechanism
that eliminates endogenous toxins, environmental chem-
icals, and reactive metabolites (Guillemette 2003; Kalth-
off et al. 2010). Levels of N-acetylneuraminate, a
monosaccharide involved with protein and lipid glyco-
sylation, were profoundly elevated in sepsis as well. Sig-
nificant alterations in protein sialyation have been
reported in sepsis and systemic inflammation with sev-















































































































































Figure 7. Metabolites that differ between control and sham conditions in WT mice (Comparison 2). (A) Ketone metabolites are increased in
the fasted sham state. Ppara/ mice have lower ketone levels. (B) 3-methylhistidine, a marker for muscle breakdown is also elevated in the
sham condition in both strains. (C) Metabolites associated with carbohydrate metabolism are decreased and are lower in Ppara/ mice in
sepsis. See Figure S5A for calculated fold change and P values. *P < 0.05 for comparison between strains within condition, #P < 0.05 for
comparison between previous condition within strain, and §P < 0.05 for main effect only for comparison with previous condition.
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from proteins in these states (Piagnerelli et al. 2005;
Gornik et al. 2007, 2011; Novokmet et al. 2014). Addi-
tionally, pantothenate levels increased dramatically after
CLP.
Second, metabolic changes potentially associated with
decreased energy production were evident. Septic mice
had lower levels of tryptophan and niacinamide, metabo-
lites essential to NAD+ biosynthesis (Fig. 6C), and low
biotin, which is an enzymatic cofactor for mitochondrial
carboxylation reactions (Fig. 8B). We also noted reduced
levels of the ketone acetoacetate compared with the sham
condition, which we and others have previously observed
in sepsis (Fig. 7A) (Lanza-Jacoby et al. 1990; Standage
et al. 2017).
Metaboanalyst evaluation identified pathways related to
glucuronate and inositol metabolism, pantothenate and
coenzyme A metabolism, and the TCA cycle as differentially
regulated between sham and CLP conditions (Fig. S7).
Comparison 5
Metabolite differences between WT and Ppara/ mice in
the septic condition provide further evidence of renal
function impairment, exacerbated inflammation, and
metabolic derangement. Xanthosine, urate, and the
polyamines, cadaverine and putrescine, were considerably
elevated in the Ppara/ mice and are associated with
kidney failure (Fig. 9A) (Campbell et al. 1978; Saito et al.
1983; Igarashi et al. 2006; Rhee et al. 2010; Goek et al.
2013; Zhang et al. 2016; Hocher and Adamski 2017; Hus-
sain et al. 2017; Srivastava et al. 2018). Oxidized lipids
mediate inflammatory signaling and are associated with
kidney injury (Rhee et al. 2010). The abundance of two
of these lipoxygenase products (12-HETE and 13-HODE)
were dramatically elevated in the Ppara/ mice along
with their polyunsaturated fatty acid precursors (linoleic
and linolenic acid; Fig. 9B). Xanthosine, glucose-1-phos-
phate, urate, and adenylosuccinate are all metabolites
involved with nucleotide biosynthesis, degradation, and
salvage pathways (Nelson and Cox 2012) and might rep-
resent increased cell death as nucleic acid metabolites are
released for recycling.
Carbohydrate metabolites decreased following CLP in
the serum of Ppara/ versus WT mice (Fig. 7C) indicat-
ing increased cellular reliance on glucose as well as
impaired gluconeogenic capacity in the absence of suffi-
cient FAO. Regarding other possible metabolic stress
responses observed in WT mice, although Ppara/ mice
augmented glucoronate levels similar to WT mice, they
did not increase N-acetylneuraminate to the same degree,
nor do they raise serum pantothenate levels (Fig. 8A).
Shikimic acid, a precursor of tryptophan biosynthesis
related to NAD+ metabolism, was also lower in Ppara/
mice (Fig. 6C).
Pathway analysis identified metabolic processes associ-
ated with pantothenate and CoA biosynthesis, carbohy-
drate and lipid metabolism as the most discrepant in this
comparison (Fig. 10).
Septic children with genome-wide
expression profiles characterized by PPARa
suppression exhibit more kidney injury
Using unsupervised genome-wide expression profiling, we
previously identified two endotypes of septic shock in



















































































Figure 8. Metabolites that differ between sham and CLP conditions in WT mice (Comparison 4). (A) Metabolites associated with stress
responses are elevated in the CLP over the sham condition. Ppara/ mice do not increase N-acetylneuraminate or pantothenate abundance
like WT mice. (B) Biotin is decreased in sepsis in both genotypes. See Figure S7A for calculated fold change and P values. *P < 0.05 for
comparison between strains within condition, #P < 0.05 for comparison between previous condition within strain, and §P < 0.05 for main
effect only for comparison with previous condition.
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2008; Wong et al. 2009a,b). Children with endotype A
were found to have higher severity of illness (PRISM-III
scoring), greater number of organ system failures, and
decreased survival compared to endotype B. A notable
feature of endotype A is repression of genes correspond-
ing to the PPARa signaling pathway (Standage et al.
2012).
We assessed whether children with septic shock classified
as endotype A by their genome-wide expression profiles
demonstrated more AKI than children classified under
endotype B. Development or persistence of stage III AKI
(severe) by day 3 of septic shock was the primary analysis
outcome. One hundred and ninety-three subjects had both
endotype and day 3 creatinine data, which we used to stage
AKI. None of the subjects had baseline kidney disease.
Thirty-three (17%) had stage three AKI on day 3 of septic
shock. As shown in the Table 1, after accounting for base-
line illness severity (PRISM-III score) and age, assignment
to endotype A was independently associated with increased







































































































Figure 9. Metabolites that differ between WT and Ppara/ mice in the CLP condition (Comparison 5). (A) Metabolites associated with renal
failure are elevated in Ppara/ over WT mice in sepsis. (B) Ppara/ mice have much higher levels of inflammatory oxygenated lipids and their
precursors than WT mice in sepsis. See Figure 10A for calculated fold change and P values. *P < 0.05 for comparison between strains within
condition, #P < 0.05 for comparison between previous condition within strain.
Table 1. Children with septic shock endotype characterized by
PPARa suppression are at greater risk of severe AKI.
Variable OR 95% CI P value
Endotype 2.50 1.04–6.0 0.04
PRISM-III 1.12 1.07–1.17 <0.001
Age 0.99 0.86–1.13 0.85
Multivariable logistic regression testing for the association
between endotype outcome variable and stage 3 AKI on day 3 of
septic shock. Adjusted for PRISM-III score and age.
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Comparison 5: CLP Wild type vs. Ppara–/–
Metabolite Contrast First.mean Second.mean esmate SE df t.rao p.value fdr.p Fold.change Priority.score
12-HETE CLP_WT.v.KO 684297.8671 7969027.533 7284729.666 1342772.104 43 5.425142243 2.49E-06 1.21E-05 11.64555366 131.855
Xanthosine CLP_WT.v.KO 18851.95454 275379.3531 256527.3986 55670.25996 43 4.607979175 3.61E-05 1.33E-04 14.60746962 130.422
Cadaverine CLP_WT.v.KO 58501.29901 302712.6716 244211.3726 25869.69054 43 9.440057747 4.82E-12 8.55E-11 5.174460682 119.959
Glucose 1-phosphate CLP_WT.v.KO 757592.8237 2327612.495 1570019.672 241951.3268 43 6.488989717 7.10E-08 5.42E-07 3.072379281 44.327
13-HODE CLP_WT.v.KO 409527.3963 1186448.844 776921.4481 134013.7839 43 5.797324914 7.20E-07 4.07E-06 2.897117153 35.958
Urate CLP_WT.v.KO 856659.9856 5683128.962 4826468.976 1631840.489 43 2.957684289 0.005019837 0.010551339 6.634054417 30.195
Adenylosuccinate CLP_WT.v.KO 53789.39837 115718.1641 61928.76573 10102.05422 43 6.130314129 2.36E-07 1.55E-06 2.151319175 28.773
Asparc Acid CLP_WT.v.KO 956543.5412 1570650.517 614106.9759 83947.65165 43 7.315356223 4.51E-09 4.53E-08 1.642006296 27.767
Glycerol-3-P CLP_WT.v.KO 2377535.696 4093284.01 1715748.315 260358.5958 43 6.589943034 5.07E-08 4.03E-07 1.721649865 25.352
Linoleic Acid CLP_WT.v.KO 205644.1454 371562.0446 165917.8992 35079.17217 43 4.729812278 2.44E-05 9.22E-05 1.806820437 16.789
Linolenic Acid CLP_WT.v.KO 3990849.853 6493287.608 2502437.755 508877.0373 43 4.917568629 1.33E-05 5.62E-05 1.627043824 15.924
Cysne CLP_WT.v.KO 200455.6475 390077.8383 189622.1908 45812.14466 43 4.139124945 1.59E-04 5.11E-04 1.945955842 14.749
Putrescine CLP_WT.v.KO 1745148.202 1902666.977 157518.7756 25957.02522 43 6.068444833 2.91E-07 1.85E-06 1.090260974 14.393
Oxaloacetate CLP_WT.v.KO 1571531.575 2570097.385 998565.8096 261142.2813 43 3.823838119 4.19E-04 0.001189314 1.63540932 11.013
Arginine CLP_WT.v.KO 3345390.863 10169826.64 6824435.78 2994153.017 43 2.27925418 0.027674656 0.047238843 3.0399517 9.28
Cytosine CLP_WT.v.KO 68480.40485 103962.0596 35481.65479 10390.90375 43 3.414684195 0.001404203 0.003456151 1.518128578 8.604
Choline CLP_WT.v.KO 52644085.75 63691682.23 11047596.48 3060603.771 43 3.60961343 7.95E-04 0.002095487 1.209854465 7.462
MethylSuccinate CLP_WT.v.KO 757131.0578 1504147.29 747016.2321 300831.5421 43 2.483171236 0.01700017 0.030883641 1.986640588 6.909
Leucine CLP_WT.v.KO 19237499.58 27454567.57 8217067.995 2905614.575 43 2.827996551 0.007085097 0.014301399 1.427138047 6.062
Orotate CLP_WT.v.KO 502875.6958 735677.0441 232801.3482 94080.96074 43 2.474478857 0.017365262 0.031397996 1.462940146 5.063
Sorbitol CLP_WT.v.KO 77617.01639 104309.1354 26692.11899 10606.02444 43 2.516694087 0.015656544 0.028716209 1.343895195 4.771
2-Hydroxyglutarate CLP_WT.v.KO 1264437.184 1487523.586 223086.4026 85244.45374 43 2.617019558 0.012192944 0.022858025 1.176431384 4.445
Lactate CLP_WT.v.KO 111331222 129881056.1 18549834.19 7440066.86 43 2.493234878 0.016586198 0.030275764 1.166618437 4.08
Erythrose CLP_WT.v.KO 102708.4476 66575.2873 –36133.16028 15078.97563 43 –2.396260938 0.020984589 0.03689226 –1.542741335 –5.091
Glyceraldehyde CLP_WT.v.KO 914880.2028 548132.0679 –366748.1349 155936.2129 43 –2.351911259 0.023326781 0.040359034 –1.669087172 –5.358
Glutaric Acid CLP_WT.v.KO 543403.5513 437348.3196 –106055.2317 35828.45327 43 –2.960084013 0.004987558 0.010512449 –1.242496031 –5.66
Acetylcarnine CLP_WT.v.KO 36819151.35 26352070.37 –10467080.97 3731391.516 43 –2.805141441 0.007522377 0.014946807 –1.397201466 –5.873
Hisdine CLP_WT.v.KO 13529098.11 10766378.68 –2762719.431 791639.648 43 –3.489869965 0.00112952 0.002825652 –1.256606192 –7.375
3-Methyl-2-Oxovaleric Acid CLP_WT.v.KO 192836.7401 154736.6431 –38100.09694 10817.21122 43 –3.522173706 0.00102801 0.002605886 –1.246225433 –7.415
Glucose CLP_WT.v.KO 76206277.22 47286765.95 –28919511.27 9428225.723 43 –3.067333358 0.003728225 0.00817424 –1.611577271 –7.746
Carnine CLP_WT.v.KO 5704427.338 3448058.838 –2256368.5 582958.0241 43 –3.870550549 3.64E–04 0.001059974 –1.65438805 –11.332
Dimethylglycine CLP_WT.v.KO 1784509.144 1257345.413 –527163.7305 121457.5378 43 –4.340313 8.48E–05 2.85E-04 –1.419267231 –11.585
Trimethylamine CLP_WT.v.KO 419311.0342 249909.4091 –169401.6251 42079.06133 43 –4.025793821 2.26E–04 6.94E-04 –1.677852129 –12.204
Succinate CLP_WT.v.KO 5935710.37 4013212.512 –1922497.858 432962.3174 43 –4.440335291 6.18E–05 2.15E-04 –1.479042127 –12.489
Fructose CLP_WT.v.KO 1797602.122 1198837.967 –598764.1552 133843.8762 43 –4.473601426 5.56E–05 1.97E-04 –1.499453781 –12.792
N-acetylneuraminate CLP_WT.v.KO 1525618.622 749299.9592 –776318.6631 155036.5873 43 –5.007325541 9.88E–06 4.31E-05 –2.036058595 –20.467
Deoxycydine CLP_WT.v.KO 35324.68293 17139.17001 –18185.51292 3286.270797 43 –5.533784048 1.74E–06 8.88E-06 –2.0610498 –23.972
Shikimic Acid CLP_WT.v.KO 43509392.41 12227642.25 –31281750.16 6354882.991 43 –4.922474608 1.30E–05 5.56E-05 –3.558281436 –34.862
Pantothenate CLP_WT.v.KO 22918945.06 6582302.399 –16336642.66 1528677.456 43 –10.68678196 1.11E–13 3.84E-12 –3.481904001 –91.526
B
MetaboAnalyst pathway evaluation



















Gly, Ser, Thr metabolism
Val, Leu, Ile metabolism
Glycerolipid metabolism
Amino & nucleotide sugar metabolism
Pathway Total Cmpd Hits Raw p –LOG(p) Holm adjust FDR Impact
Pantothenate and CoA biosynthesis 15 3 1.98E-06 13.135 0.00010274 6.04E-05 0.02041
Galactose metabolism 26 5 3.20E-06 12.651 0.00016341 6.04E-05 0.15932
Starch and sucrose metabolism 19 6 3.49E-06 12.567 0.00017431 6.04E-05 0.21925
Biosynthesis of unsaturated fay acids 42 2 6.66E-05 9.6168 0.0032633 0.00070599 0
alpha-Linolenic acid metabolism 9 1 6.79E-05 9.5977 0.0032633 0.00070599 1
Citrate cycle (TCA cycle) 20 5 0.00023955 8.3368 0.011259 0.0020761 0.30648
Linoleic acid metabolism 6 2 0.00042336 7.7673 0.019474 0.0031449 1
Propanoate metabolism 20 2 0.0014028 6.5693 0.063125 0.008169 0
Amino sugar and nucleode sugar metabolism 37 3 0.0014139 6.5614 0.063125 0.008169 0.08058
beta-Alanine metabolism 17 2 0.0018832 6.2748 0.080978 0.0097927 0
Glycerolipid metabolism 18 3 0.0031169 5.7709 0.13091 0.014735 0.13031
Fructose and mannose metabolism 21 2 0.0070298 4.9576 0.28822 0.030462 0.03881
Tyrosine metabolism 44 5 0.0098461 4.6207 0.39384 0.038542 0.15459
Purine metabolism 68 6 0.010377 4.5682 0.40469 0.038542 0.06431
Aminoacyl-tRNA biosynthesis 69 19 0.01323 4.3253 0.50274 0.045515 0.12903
Glycerophospholipid metabolism 30 4 0.014415 4.2395 0.53337 0.045515 0.11204
Glycine, serine and threonine metabolism 31 11 0.015726 4.1524 0.56613 0.045515 0.63044
Ubiquinone and other terpenoid-quinone biosynthesis 3 1 0.018243 4.004 0.63849 0.045515 0
Valine, leucine and isoleucine biosynthesis 11 4 0.018623 3.9834 0.63849 0.045515 0.99999
Methane metabolism 9 2 0.019622 3.9311 0.64754 0.045515 0.4
Cyanoamino acid metabolism 6 2 0.019622 3.9311 0.64754 0.045515 0
Valine, leucine and isoleucine degradaon 38 5 0.020041 3.91 0.64754 0.045515 0
Sphingolipid metabolism 21 1 0.020132 3.9055 0.64754 0.045515 0
Cysteine and methionine metabolism 27 4 0.021137 3.8567 0.64754 0.045796 0.1351
Hisdine metabolism 15 3 0.022437 3.7971 0.64754 0.046668 0.24194
Figure 10. Lists of differentially abundant metabolites and altered metabolic pathways between WT and Ppara/ mice in sepsis. (A) In the
CLP condition, Ppara/ serum metabolic profile is characterized by increased levels of metabolites associated with renal failure, inflammatory
lipids, and nucleic acid turnover. Additionally, Ppara/ mice had lower levels of pantothenate and N-acetylneuraminate, metabolites associated
with stress responses, as well as decreased amounts of metabolites involved with tryptophan, carbohydrate, and lipid metabolism. This list was
generated by analyzing differences between strain and condition using two-factor ANOVA for each metabolite. Pairwise, post-estimation
contrasts were made for each metabolite that had a significant interaction term. P values for these comparisons were adjusted using an FDR of
0.5 and only the significantly different metabolites were included in the list. Metabolites were ranked using a priority score calculated as the
product of the fold change and negative log of the P value. (B) Pathway analysis using MetaboAnalyst revealed that pathways involving
pantothenate, carbohydrate, TCA, and fatty acid metabolism as most different between WT and Ppara/ mice in sepsis. Only significantly
altered pathways are included in the list.
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Discussion
Using a model of experimental polymicrobial sepsis, we
have shown that Ppara/ mice develop AKI while their
WT counterparts do not. Serum BUN and creatinine
levels are increased in septic Ppara/ mice and a far
greater proportion of Ppara/ mice become anuric after
CLP. Even with the mild insult of sham operation,
Ppara/ mice have elevated urinary protein levels, which
point to an underlying vulnerability to AKI.
Gene expression markers of injury (KIM-1 and NGAL)
and inflammation (IL-6) are specifically upregulated in
the Ppara/ kidney. Our finding that mRNA expression
levels of many lipid transporters and FAO enzymes are
decreased in Ppara/ mice are consistent with the
known regulatory influence of PPARa on those genes and
findings from previous studies (Feingold et al. 2008;
Rakhshandehroo et al. 2010). Protein levels of two FAO
enzymes, ACADM and ACADVL, were also lower in the
Ppara/ kidney tissue indicating that translational regu-
lation of these pathways is commensurate with their tran-
scriptional regulation.
Ultrastructural changes noted with electron microscopy
in the proximal tubular epithelial cells clearly demonstrate
evidence of decreased FAO and worse injury in the septic
Ppara/ kidney. The presence of lipid droplets in the
Ppara/ proximal tubules in both control and CLP con-
ditions indicates a constitutively low level of FAO that
potentiates sepsis-associated injury because the proximal
tubule specifically is so highly reliant on FAO for ATP
production (Weidemann and Krebs 1969; Bobulescu
2010). This finding is consistent with the observed lower
expression of lipid transporters and FAO enzymes in that
strain. Interestingly, WT mice do not have lipid droplets
in the control condition, but develop them after CLP
despite demonstrating no changes in FAO enzyme expres-
sion and maintaining adequate renal function. Although
WT mice do not show a statistically significant increase in
IL-6, expression of IL-1b and TNFa is elevated in the CLP
condition for both WT and Ppara/ mice. Inflammation
suppresses FAO in the kidney, which has been well
described in multiple renal injury models (Johnson et al.
2005; Zager et al. 2005; Feingold et al. 2008; Takahashi
et al. 2011). Metabolic pathway regulation can occur at
the transcriptional, translational, and posttranslational
levels and metabolic pathway flux may be altered without
seeing changes in enzyme expression. We propose that a
threshold effect may be at play in the development of lipid
droplets and AKI in our model. Control WT mice do not
have lipid droplets because they have normal levels of
FAO. Ppara/ mice have lower levels of FAO and mani-
fest lipid droplets at baseline without significant evidence
of renal dysfunction. Sepsis-induced inflammation
suppresses FAO in both strains. While the relative degree
of this suppression only results in the development of lipid
droplets in WT mice, in Ppara/ mice that start with
lower levels of FAO, proximal tubules develop critical
energy limitations that compromise functional capacity.
Loss of brush border architecture observed in Ppara/
mice indicates failure of the absorptive and excretory
functions of the proximal tubule essential to renal
function. Dramatically increased abundance of
autophagosomes points toward the presence two poten-
tial cellular pathologies addressed by autophagy: (1)
damaged and dysfunctional organelles in need of recy-
cling, (2) energy depletion (Kroemer et al. 2010). This
second problem is likely especially active in the Ppara/
 mice that cannot meet increased ATP demands by
FAO. They may therefore undertake autophagy to pro-
vide an alternative energy supply. Sunahara et al.
(2018) recently showed that WT C57/B6 mice subjected
to CLP-induced sepsis had increased autophagy in renal
tubular epithelial cells 6–8 h after surgery, that
decreased toward sham-operated levels at 24 h. Our
WT mice had only a mild elevation in the qualitative
abundance in autophagosomes at 24 h, which could be
consistent with Sunahara et al., but we did not evaluate
our animals at the 6–8 h time point. Autophagy has
been shown to be augmented in the liver by PPARa
signaling (Jiao et al. 2014; Lee et al. 2014), but no
reports have previously evaluated the relationship
between autophagy and PPARa in the kidney. Augmen-
tation of autophagy in our Ppara/ mice would neces-
sarily be mediated by other signaling pathways.
The most salient finding from our metabolomic study
in septic mice is that metabolites associated with renal
failure and inflammation have significantly increased
abundance in the Ppara/ cohort. This is consistent with
other results reported in this manuscript: serum and
urine markers of kidney function as well as tissue expres-
sion of genes activated in renal injury and inflammation.
PPARa is well known to impose a generally anti-inflam-
matory influence on the immune response (Wahli and
Michalik 2012; Bougarne et al. 2018). It is therefore not
surprising that tissue and circulating mediators of inflam-
mation are higher in Ppara/ mice with sepsis. Accom-
panying these observations are multiple signatures of
metabolic dysfunction in the Ppara/ mice.
The metabolomics analysis recapitulated our previous
findings that Ppara/ mice fail to mobilize ketones in
the fasted state and that they have lower circulating levels
of carbohydrate substrate (Standage et al. 2017). Ppara/
mice also have elevation of metabolites associated with
the urea cycle across all conditions, indicating increased
reliance on amino acids for energy production, a depen-
dence that also imposes an increased excretory burden on
2019 | Vol. 7 | Iss. 10 | e14078
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the kidney to eliminate attendant nitrogenous wastes.
They also demonstrate lower levels of carnitine necessary
for transport and oxidation of fatty acids, which is
expected due to the dependency of that pathway on
PPARa regulation.
We detected unanticipated evidence of metabolic
defects in the Ppara/ mice in the tryptophan-kynure-
nine-NAD+ and pantothenate pathways, both of which
are central to cellular metabolism. Over 95% of trypto-
phan in the body is metabolized to NAD+ for utilization
in bioenergetic processes (Cervenka et al. 2017). This
pathway flows through various kynurenine compounds
which have been shown to be dysregulated in inflamma-
tion and sepsis (Chen and Guillemin 2009; Changsiri-
vathanathamrong et al. 2011; Mangge et al. 2014) as well
as in chronic kidney disease (Goek et al. 2013; Hocher
and Adamski 2017). Recent, important work has shown
that kidney NAD+ biosynthesis is directly related to FAO
and renal injury in model organisms and human studies
(Tran et al. 2016; Poyan Mehr et al. 2018). Furthermore,
PPARa regulates enzymes in the tryptophan-kynurenine-
NAD+ biosynthetic pathway, including quinolinate phos-
phoribosyltransferase, which performs the final step of
NAD+ synthesis (Shin et al. 1999; Agudelo et al. 2014).
PPARa may therefore have an important role in cellular
energy provision beyond merely maintaining FAO.
The significant elevation of pantothenate levels in septic
WT mice and their lack of change in Ppara/ mice are
another potentially important feature. Pantothenate is an
essential nutrient incorporated into the coenzyme A
molecule, which serves as an indispensable cofactor for
many central metabolic reactions (Leonardi et al. 2005).
In states of physiologic stress, coenzyme A is hydrolyzed
to produce pantetheine, which is further cleaved by vanin
enzymes to yield pantothenate and cysteamine, which has
antioxidant and cytoprotective effects (Pitari et al. 2000;
Berruyer et al. 2004; Naquet et al. 2014). PPARa regulates
the vanin pantetheinase enzyme (Rommelaere et al. 2013;
van Diepen et al. 2014). Increased pantothenate abun-
dance could possibly represent a stress response mecha-
nism involving pantetheine cleavage from coenzyme A to
produce cysteamine that Ppara/ mice lack.
The clinical relevance of these findings is highlighted
by our analysis of critically ill children with septic shock.
We saw that children categorized according to genome-
wide expression profiles as sepsis endotype A, which is
characterized by profound suppression of the PPARa sig-
naling pathway, had much greater odds of severe AKI
than children assigned to endotype B. To our knowledge
similar findings have not previously been reported.
We readily acknowledge some limitations of this
work. First, animal models do not recapitulate perfectly
human disease (Seok et al. 2013; Osuchowski et al.
2014; Takao and Miyakawa 2015). We have taken care,
however, to make our model clinically relevant by tar-
geting a WT mortality of about 20–25% at 7 days and
administering fluids, antibiotics, and analgesics (Standage
et al. 2016). Another limitation is that we utilized whole
body Ppara/ mice and we have shown previously that
these mice have cardiac dysfunction and dysregulation
serum levels of metabolic substrate (Standage et al.
2017). It is plausible to attribute poor renal function in
Ppara/ mice to poor cardiac function. To address this
question, we are currently developing a tissue-specific
Ppara/ mouse. Despite this possibility, other kidney
injury models not dependent on cardiac function have
shown that PPARa has direct importance in preventing
AKI (Portilla et al. 2006; Li et al. 2012, 2013). Further-
more, our EM analysis showed specific proximal tubular
injury in the Ppara/ kidney and it is known that the
epithelial cells that comprise this tubule are highly reli-
ant on FAO for energy provision (Weidemann and
Krebs 1969). Another limitation is that we did not
directly demonstrate lower FAO in the Ppara/ kidney
or the CLP condition, but rather inferred it from our
gene and protein expression experiments and several
published reports that show reduction of FAO in the
Ppara/ kidney and in the injured WT kidney (Portilla
2003; Johnson et al. 2005; Zager et al. 2005; Tanaka
et al. 2011; Li et al. 2012; Simon and Hertig 2015). In
future studies using kidney-specific PPARa deletion, we
will directly quantify renal cortical lipid levels and rates
of FAO. Finally, our clinical findings in children with
septic shock are retrospective in nature. The data ana-
lyzed, however, were collected prospectively as part of a
large, ongoing, multicenter clinical/translational investi-
gation, thus minimizing potential bias.
In conclusion, we have shown an association between
PPARa expression and sepsis-associated AKI in our
experimental model. The mechanism whereby PPARa
could contribute to maintenance of renal function likely
relies on augmentation of FAO and other metabolic
pathways necessary for cellular energy provision and by
reduction of tissue and circulating inflammatory media-
tors. Our corroborative clinical data indicate that simi-
lar PPARa dependent processes may be operative in
human sepsis. Future investigation is necessary to con-
firm these findings and elucidate rigorously the under-
lying mechanism.
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Figure S3. Individual components of proximal tubule
injury score are worse in septic Ppara/ mice. A: Two-
factor ANOVA models had significant interaction terms
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lipid droplet components of the injury score.
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